Notes

Permanent magnet Disturbance upon Cardiac Implantable Electronics Via New iphone MagSafe Engineering.
Objective To systematically assess the quality of guidelines/consensus on live cancer screening globally and provide references for the formulation of evidence-based guideline on liver cancer screening in China. Methods PubMed, Cochrane Library, China National Knowledge Infrastructure, Wanfang Data, SinoMed, and other related guideline development institutions were searched to identify guidelines on live cancer screening before June 30, 2020. Two experienced reviewers screened literature and extracted data independently. The Appraisal of Guidelines for Research & Evaluation Ⅱ(AGREE Ⅱ) and Reporting Items for Practice Guideline in Healthcare (RIGHT) were used to evaluate the quality of guidelines. find more Results A total of 19 guidelines/consensus issued between 2003 and 2019 were included in this study. The quality of these guidelines was high according to AGREE Ⅱ, nine of which were recommended as level A, and the other five were graded as level B. Each guidance scored higher in scope and purpose, stakeholder involvement, and clarity of presentation. The reporting quality of basic information with 56.1% reporting rate was the highest based on RIGHT. The reporting quality of background (37.5%) and recommendations (39.8%) were acceptable. However, evidence (35.8%), review and quality assurance (18.4%), funding and declaration and management of interests (22.4%) and other information (21.0%) still need to be improved. Conclusions Although the quality of screening guidelines for liver cancer is acceptable, the evidence, review and quality assurance, and funding and declaration and management of interests still need to be strengthened. There is still a lack of solely evidence-based medical screening guidelines for liver cancer in China.Objective To systematically review the quality of clinical practice guidelines for prostate cancer screening to serve as a reference for developing prostate cancer screening guidelines in China. Methods We searched PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Wanfang Data, and SinoMed with the term "prostate cancer" "prostate carcinoma" "prostate tumor" "screening" "early detection" "guideline" "recommendation" as keywords. The Appraisal of Guidelines for Research & Evaluation (AGREE) Ⅱ instrument and Reporting Items for Practice Guidelines in Healthcare (RIGHT) were used for critical appraisal. Results A total of thirteen guidelines were included in this review. Evaluated by the AGREE Ⅱ instrument, ten were considered as A level. Two guidelines scored B level, and one was considered C level. Lowest mean domain scores were for stakeholder involvement (52.1%) and applicability (34.0%). Using the RIGHT checklist, we found that the low reporting quality of the thirteen guidelines could be attributable to incomplete disclosure of evidence (64.6%), funding, declaration and management of interest (44.2%), or other information (46.2%). Conclusions No guidelines for prostate cancer screening was developed in China. The methodological quality of the guidelines in prostate cancer screening was good, which set a tone for the development of Chinese guidelines. However, all guidelines showed poor reporting quality.Objective To evaluate the quality of the published breast cancer screening guidelines to provide a reference for domestic studies in the future. Methods PubMed, Embase, Cochrane Library, Web of Science, SinoMed, China National Knowledge Infrastructure, VIP, and Wanfang Data were searched to identify breast cancer screening guidelines on until August 2020. Two reviewers screened literature and extracted data independently. The Appraisal of Guidelines for Research & Evaluation Ⅱ(AGREEⅡ) and Reporting Items for Practice Guidelines in Healthcare(RIGHT) tools were used to evaluate the quality of the included guidelines. Results A total of 15 breast cancer screening guidelines were included, of which seven were published in the United States, with publication years focusing on 2015 to 2019, and 11 guidelines had updated versions. "Rigour of development" (47.0%±22.1%) and "Applicability" (44.0%±15.1%) of AGREEⅡ scored lower than other domains. "Review and quality assurance" (46.7%±39.9%) and "Funding, declaration, and management of interests" (41.7%±24.4%) of RIGHT were reported poorer than others. There were six guidelines recommended and another nine recommended with modifications based on the overall AGREEⅡ score. There were four guidelines with a good level, and another 11 were with a moderate level of RIGHT. The National Comprehensive Cancer Network published the best overall quality guidelines in 2018 (AGREEⅡ 83.3%, RIGHT 80.0%) and by the American Cancer Society in 2015 (AGREEⅡ 83.3%, RIGHT 85.7%). Conclusion The quality of breast cancer screening guidelines was predominantly of moderate quality, and greater attention should be paid to the guideline development process and quality control of the guidelines.The current situation of AIDS prevention and control is still challenging in China. Although China has made great progress in expanding HIV testing and promoting case identification, there are still a large number of HIV-infected individuals who have not been identified, which might influence the overall achievement of the goal of HIV/AIDS prevention and control. Thus, China needs to further promote self-testing while conducting routine HIV testing and use it as a supplement to further expand HIV testing coverage. The articles in this issue focus on the global situation of HIV self-testing services, reports the changes of self-testing among MSM in China from 2013 to 2018, and compares the effects of different HIV/syphilis self-testing models in promoting HIV/syphilis testing in key populations in order to achieve the overall goal of AIDS prevention and control in China.Cancer screening is one of approaches to reduce cancer mortality. Standardized cancer screening technology guidelines are the main way to improve scientific standardization and internationalization. With the development of development methodology on guideline making, the number of local and international cancer screening guidelines increases, but the quality is still uneven. This article summarizes the progress of the quality of cancer screening guidelines. It promotes the opportunities and challenges of cancer screening guidelines to reference high-quality cancer screening services in the future in China.
Read More: https://www.selleckchem.com/products/FK-506-(Tacrolimus).html